NEW YORK, August 17, 2017 /PRNewswire/ --
If you want a Stock Review on PFE, LLY, MRK, or SNY then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has issued research reports on four major players in the Drug Manufacturers space: Pfizer Inc. (NYSE: PFE), Eli Lilly and Co. (NYSE: LLY), Merck & Co. Inc. (NYSE: MRK), and Sanofi (NYSE: SNY). Demand for pharmaceuticals is driven by the desire to cure illness and disease. The profitability of individual pharmaceutical manufacturing companies depends on their ability to discover and market new drugs. Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in New York headquartered Pfizer Inc. saw a slight decline of 0.06%, ending Wednesday's trading session at $33.36. The stock recorded a trading volume of 10.56 million shares. The Company's shares have gained 3.51% over the last three months and 2.71% on an YTD basis. The stock is trading 0.31% and 1.26% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 51.83.
On July 20th, 2017, research firm Credit Suisse downgraded the Company's stock rating from 'Outperform' to 'Neutral'.
On July 24th, 2017, Pfizer announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective. PF-06439535 is being developed by the Company as a potential biosimilar to Avastin. The trial demonstrated equivalence in the primary endpoint of objective response rate of PF-06439535 versus Avastin, taken in combination with carboplatin/paclitaxel, for the first-line treatment of patients with advanced non-squamous, non-small cell lung cancer. Visit us today and access your complete report on PFE for free at:
Indianapolis, Indiana headquartered Eli Lilly and Co.'s stock declined 1.25%, closing the day at $80.69. A total volume of 3.97 million shares was traded, which was above their three months average volume of 3.62 million shares. The Company's shares have advanced 3.26% in the previous three months and 9.71% since the start of this year. The stock is trading 1.82% above its 200-day moving average. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 38.03.
On July 26th, 2017, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.
On August 04th, 2017, Eli Lilly announced that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase-3 study. At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo. These results were statistically significant across all three studied doses: 50 mg, 100 mg and 200 mg. The complimentary research report on LLY can be accessed at:
On Wednesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 6.05 million shares. The stock ended the day 0.32% higher at $62.70. The Company's shares have advanced 0.46% in the past month and 6.51% on an YTD basis. The stock is trading below its 200-day moving average by 0.46%. Furthermore, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 47.50.
On July 27th, 2017, Merck, known as MSD outside the US and Canada, announced that singer-songwriter and actress Mandy Moore is teaming up with the Company to launch Her Life. Her Adventures to encourage women to plan ahead and get educated about family planning, including birth control options, so they can prepare for life's adventures. The campaign highlights the importance of making a plan as women pursue their goals.
On August 09th, 2017, research firm HSBC Securities upgraded the Company's stock rating from 'Reduce' to 'Hold'. Register for free on DailyStockTracker.com and download the research report on MRK at:
Paris, France headquartered Sanofi's stock climbed 1.25%, finishing yesterday's session at $48.43 with a total trading volume of 1.31 million shares. The Company's shares have advanced 1.45% in the last one month and 19.76% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.79% and 9.02%, respectively. Additionally, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have an RSI of 56.64.
On July 31st, 2017, Sanofi announced that its half-year financial report for the period ending June 30th, 2017, is available and has been filed with the French market regulator Autorité des marchés financiers and submitted to the US SEC under form 6-K. This document may be found on the Company's corporate website. Get free access to your research report on SNY at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA